US FDA grants approval to Lecanemab, an Alzheimer’s drug

• US Food and Drug Administration has granted approval to Alzheimer’s drug lecanemab (marketed as Leqembi) that has shown to slow cognitive decline in patients in early stages of the illness.
• Lecanemab aims to slow the progression of disease by removing clumps of beta-amyloid —considered one of the main causes of Alzheimer’s disease — from the brain.

What is Alzheimer’s?

• Alzheimer’s disease is a progressive neurologic disorder that causes the brain to shrink (atrophy) and brain cells to die.
• It is the most common cause of dementia — a continuous decline in thinking, behavioral and social skills .